WS #16231
Abbott Laboratories is undertaking a significant structural change by spinning off its global Nutrition business into an independent public company, expected to complete by the end of 2027. This move is designed to unlock value by allowing the two entities to pursue distinct growth strategies in their respective markets. The spin-off is viewed positively by investors seeking focused exposure to Abbott's core healthcare and diagnostics segments.
Corporate Restructuring & Spin-offs
Abbott Laboratories is undertaking a significant structural change by spinning off its global Nutrition business into an independent public company, expected to complete by the end of 2027. This move is designed to unlock value by allowing the two entities to pursue distinct growth strategies in their respective markets. The spin-off is viewed positively by investors seeking focused exposure to Abbott's core healthcare and diagnostics segments.